Design, synthesis and evaluation of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes

被引：0
作者：
Das, Saibal Kumar [1 ]
Abbineni, Chandrasekhar [1 ]
Rao, Krovvidi Venkata Lakshmi Narasimha [1 ]
Iqbal, Javed [1 ]
Babu, Ravi Krishna [1 ]
Chakrabarti, Ranjan [1 ]
机构：
[1] Dr Reddys Labs Ltd, Metab Disorders Grp, Discovery Res, Hyderabad 500049, Andhra Pradesh, India
来源：
LETTERS IN DRUG DESIGN & DISCOVERY | 2007年 / 4卷 / 01期
关键词：
PPAR; diabetes; synthesis; ethyl 3-(4-aminophenyl)-2-ethoxypropionate; dyslipidemia and plasma glucose;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The design, synthesis and evaluation of several dual PPAR alpha/gamma agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPAR alpha/gamma agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.
引用
收藏
页码：27 / 32
页数：6
相关论文
共 50 条
  • [41] Peroxisome proliferator-activated receptor ligands in atherosclerosis
    Viles-Gonzalez, JF
    Choi, BG
    Fuster, V
    Badimon, JJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) : 1393 - 1403
  • [42] Stabilization of peroxisome proliferator-activated receptor α by the ligand
    Hirotani, M
    Tsukamoto, T
    Bourdeaux, J
    Sadano, H
    Osumi, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (01) : 106 - 110
  • [43] Genetic polymorphisms in peroxisome proliferator-activated receptor γ are associated with Type 2 diabetes mellitus and obesity in the Korean population
    Moon, MK
    Cho, YM
    Jung, HS
    Park, YJ
    Yoon, KH
    Sung, YA
    Park, BL
    Lee, HK
    Park, KS
    Shin, HD
    DIABETIC MEDICINE, 2005, 22 (09) : 1161 - 1166
  • [44] Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on type 2 diabetes risk
    Ludovico, Ornella
    Pellegrini, Fabio
    Di Paola, Rosa
    Minenna, Antonio
    Mastroianno, Sandra
    Cardellini, Marina
    Marini, Maria Adelaide
    Andreozzi, Francesco
    Vaccaro, Olga
    Sesti, Giorgio
    Trischitta, Vincenzo
    OBESITY, 2007, 15 (05) : 1076 - 1081
  • [45] In silico approach for discovery of drug against the peroxisome proliferator-activated receptor gamma for diabetes treatment
    Allahabi, Zeyad
    Singh, Sanjeev
    ANNALS OF PHYTOMEDICINE-AN INTERNATIONAL JOURNAL, 2022, 11 (01): : 299 - 310
  • [46] Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and Type 2 diabetes
    Seda, Ondrej
    Sedova, Lucie
    PHARMACOGENOMICS, 2007, 8 (06) : 587 - 596
  • [47] Peroxisome proliferator-activated receptor (PPAR) agonists as a potential therapy for inherited metabolic disorders
    Seminotti, Bianca
    Grings, Mateus
    Vockley, Jerry
    Leipnitz, Guilhian
    BIOCHEMICAL PHARMACOLOGY, 2023, 209
  • [48] Cytotoxicity of peroxisome proliferator-activated receptor α and γ agonists in renal proximal tubular cell lines
    Giral, Hector
    Villa-Bellosta, Ricardo
    Catalan, Julia
    Sorribas, Victor
    TOXICOLOGY IN VITRO, 2007, 21 (06) : 1066 - 1076
  • [49] Gene alterations by peroxisome proliferator-activated receptor γ agonists in human colorectal cancer cells
    Cekanova, Maria
    Yuan, Joshua S.
    Li, Xiuoon
    Kim, Kyubo
    Baek, Seung Joon
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 32 (04) : 809 - 819
  • [50] Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
    Cho, Nobuo
    Momose, Yu
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (17) : 1483 - 1507
12345